Finnish venture capital firm Innovestor has launched a new life science and health fund focusing on early stage opportunities in the Nordic and Baltic countries.
Pekka Simula, partner at Innovestor, says to AMWatch the fund is interested particularly in developing treatment for rare diseases and has already screened some 200 companies. The fund’s first investment, however, will most likely be published in Q2.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.